TNOX Tanox (MM)

Trial Meets Primary Endpoint HOUSTON, Oct. 26 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today reported positive Phase 2 clinical results of its novel HIV drug candidate, TNX-355. The 24-week results of the study show that TNX-355 at the 10 mg/kg dose, when given in combination with optimized background therapy (OBT), produced a considerably greater reduction in viral load in HIV-infected patients than did placebo in combination with OBT. TNX-355 was well tolerated, with no serious adverse events related to the drug. The study met its primary endpoint with TNX-355 plus OBT demonstrating a statistically significant reduction in viral load -- the level of HIV in the bloodstream -- compared to placebo plus OBT at Week 24. Treatment with the 10 mg/kg dose of TNX-355 resulted in a viral-load reduction of 1.16 log10, compared with a 0.20 log10 reduction in the placebo group, representing a 0.96 log10 greater reduction (p